{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T14:59:23Z","timestamp":1770994763603,"version":"3.50.1"},"reference-count":88,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2017,4,4]],"date-time":"2017-04-04T00:00:00Z","timestamp":1491264000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Diab Rep"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1007\/s11892-017-0859-2","type":"journal-article","created":{"date-parts":[[2017,4,4]],"date-time":"2017-04-04T23:45:52Z","timestamp":1491349552000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Pharmacotherapy of Obesity: Clinical Trials to Clinical Practice"],"prefix":"10.1007","volume":"17","author":[{"given":"Kishore M.","family":"Gadde","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Pritham Raj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,4,4]]},"reference":[{"key":"859_CR1","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1016\/S0140-6736(05)67483-1","volume":"366","author":"DW Haslam","year":"2005","unstructured":"Haslam DW, James WPT. Obesity. Lancet. 2005;366:1197\u2013209.","journal-title":"Lancet"},{"issue":"suppl 2","key":"859_CR2","doi-asserted-by":"crossref","first-page":"S102","DOI":"10.1161\/01.cir.0000437739.71477.ee","volume":"129","author":"MD Jensen","year":"2014","unstructured":"\u2022\u2022 Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA\/ACC\/TOS guideline for the management of overweight and obesity in adults. Circulation. 2014;129(suppl 2):S102\u201338. Recently published guideline for the management of obesity co-developed by the American College of Cardiology, American Heart Association, and The Obesity Society","journal-title":"Circulation"},{"key":"859_CR3","unstructured":"National Heart. Lung, and Blood Institute, National Institutes of Health. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: the evidence report. Bethesda, MD. NIH Publication No. 98\u20134083, National Institutes of Health, September 1998."},{"key":"859_CR4","doi-asserted-by":"crossref","first-page":"373","DOI":"10.7326\/0003-4819-157-5-201209040-00475","volume":"157","author":"VA Moyer","year":"2012","unstructured":"Moyer VA. Screening for and management of obesity in adults: U.S. preventive services task force recommendation. Ann Intern Med. 2012;157:373\u20138.","journal-title":"Ann Intern Med"},{"key":"859_CR5","first-page":"123","volume":"13","author":"FM Kramer","year":"1989","unstructured":"Kramer FM, Jeffery RW, Forster JL, Snell MK. Long-term follow-up of behavioral treatment for obesity: patterns of weight regain among men and women. Int J Obes. 1989;13:123\u201336.","journal-title":"Int J Obes"},{"key":"859_CR6","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1038\/sj.ijo.0802982","volume":"29","author":"JD Douketis","year":"2005","unstructured":"Douketis JD, Macie C, Thabane L, Williamson DF. Systematic review of long-term weight loss studies in obese adults: clinical significance and applicability to clinical practice. Int J Obes. 2005;29:1153\u201367.","journal-title":"Int J Obes"},{"key":"859_CR7","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.2337\/diacare.25.12.2165","volume":"25","author":"Diabetes Prevention Program (DPP) Research Group","year":"2002","unstructured":"Diabetes Prevention Program (DPP) Research Group. The diabetes prevention program (DPP): description of lifestyle intervention. Diabetes Care. 2002;25:2165\u201371.","journal-title":"Diabetes Care"},{"key":"859_CR8","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.2337\/dc07-0048","volume":"30","author":"The Look AHEAD Research Group","year":"2007","unstructured":"The Look AHEAD Research Group. Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial. Diabetes Care. 2007;30:1374\u201383.","journal-title":"Diabetes Care"},{"key":"859_CR9","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1001\/jama.2010.1531","volume":"304","author":"DH Ryan","year":"2010","unstructured":"Ryan DH, Kushner R. The state of obesity and obesity research. JAMA. 2010;304:1835\u20136.","journal-title":"JAMA"},{"key":"859_CR10","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJMoa1212914","volume":"369","author":"The Look AHEAD Research Group","year":"2013","unstructured":"The Look AHEAD Research Group. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med. 2013;369:145\u201354.","journal-title":"N Engl J Med"},{"key":"859_CR11","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1056\/NEJMoa1112082","volume":"367","author":"LMS Carlsson","year":"2012","unstructured":"Carlsson LMS, Peltonen M, Ahlin S, et al. Bariatric surgery and prevention of type 2 diabetes in Swedish obese subjects. N Engl J Med. 2012;367:695\u2013701.","journal-title":"N Engl J Med"},{"key":"859_CR12","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1056\/NEJMoa066603","volume":"357","author":"TD Adams","year":"2007","unstructured":"Adams TD, Gress RE, Smith SC, et al. Long-term mortality after gastric bypass surgery. N Engl J Med. 2007;357:753\u201361.","journal-title":"N Engl J Med"},{"key":"859_CR13","doi-asserted-by":"crossref","first-page":"e32506","DOI":"10.1371\/journal.pone.0032506","volume":"7","author":"RB Dorman","year":"2012","unstructured":"Dorman RB, Miller CJ, Leslie DB, et al. Risk for hospital readmission following bariatric surgery. PLoS One. 2012;7:e32506.","journal-title":"PLoS One"},{"key":"859_CR14","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1001\/archsurg.142.10.954","volume":"142","author":"T Almahmeed","year":"2007","unstructured":"Almahmeed T, Gonzalez R, Nelson LG, et al. Morbidity of anastomotic leaks in patients undergoing Roux-en-Y gastric bypass. Arch Surg. 2007;142:954\u20137.","journal-title":"Arch Surg"},{"key":"859_CR15","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1002\/bjs.7568","volume":"98","author":"K Hamdan","year":"2011","unstructured":"Hamdan K, Somers S, Chand M. Management of late postoperative complications of bariatric surgery. Br J Surg. 2011;98:1345\u201355.","journal-title":"Br J Surg"},{"key":"859_CR16","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/oby.2002.86","volume":"10","author":"JW Anderson","year":"2002","unstructured":"Anderson JW, Greenway FL, Fujioka K, et al. Bupropion SR enhances weight loss: a 48-week double-blind, placebo-controlled trial. Obes Res. 2002;10:633\u201341.","journal-title":"Obes Res"},{"key":"859_CR17","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1056\/NEJMoa050156","volume":"353","author":"TA Wadden","year":"2005","unstructured":"Wadden TA, Berkowitz RI, Womble LG, et al. Randomized trial of lifestyle modification and pharmacotherapy for obesity. N Engl J Med. 2005;353:2111\u201320.","journal-title":"N Engl J Med"},{"key":"859_CR18","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/oby.2010.147","volume":"19","author":"TA Wadden","year":"2011","unstructured":"Wadden TA, Foreyt JP, Foster GD, et al. Weight loss with naltrexone SR\/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obesity. 2011;19:110\u201320.","journal-title":"Obesity"},{"key":"859_CR19","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2337\/dc06-0210","volume":"30","author":"B Richelsen","year":"2007","unstructured":"Richelsen B, Tonstad S, R\u00f6ssner S, et al. Effect of orlistat on weight regain and cardiovascular risk factors following a very-low-energy diet in abdominally obese patients: a 3-year, randomized, placebo-controlled trial. Diabetes Care. 2007;30:27\u201332.","journal-title":"Diabetes Care"},{"key":"859_CR20","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1038\/ijo.2013.120","volume":"37","author":"TA Wadden","year":"2013","unstructured":"Wadden TA, Hollander P, Klein S, et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet induced weight loss: the SCALE maintenance randomized study. Int J Obes. 2013;37:1443\u201351.","journal-title":"Int J Obes"},{"key":"859_CR21","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/sj.ijo.0801889","volume":"26","author":"CK Haddock","year":"2002","unstructured":"Haddock CK, Poston WSC, Dill PL, et al. Pharmacotherapy for obesity: a quantitative analysis of four decades of published randomized clinical trials. Int J Obes. 2002;26:262\u201373.","journal-title":"Int J Obes"},{"key":"859_CR22","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1001\/archinte.163.9.1046","volume":"163","author":"RS Stafford","year":"2003","unstructured":"Stafford RS, Radley DC. National trends in antiobesity medication use. Arch Intern Med. 2003;163:1046\u201350.","journal-title":"Arch Intern Med"},{"key":"859_CR23","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1002\/phar.1342","volume":"33","author":"C Hampp","year":"2013","unstructured":"Hampp C, Kang EM, Borders-Hemphill V. Use of prescription antiobesity drugs in the United States. Pharmacotherapy. 2013;33:1299\u2013307.","journal-title":"Pharmacotherapy"},{"key":"859_CR24","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1056\/NEJMoa1003114","volume":"363","author":"WPT James","year":"2010","unstructured":"James WPT, Caterson ID, Coutinho W, et al. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med. 2010;363:905\u201315.","journal-title":"N Engl J Med"},{"key":"859_CR25","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1161\/CIRCULATIONAHA.105.596130","volume":"114","author":"KM Gadde","year":"2006","unstructured":"Gadde KM, Allison DB. Cannabinoid-1 receptor antagonist, rimonabant, for management of obesity and related risks. Circulation. 2006;114:974\u201384.","journal-title":"Circulation"},{"key":"859_CR26","doi-asserted-by":"crossref","first-page":"434","DOI":"10.7326\/0003-4819-155-7-201110040-00006","volume":"155","author":"ES Leblanc","year":"2011","unstructured":"Leblanc ES, O\u2019Connor E, Whitlock EP, et al. Effectiveness of primary care-relevant treatments for obesity in adults: a systematic evidence review for the U.S. preventive services task force. Ann Intern Med. 2011;155:434\u201347.","journal-title":"Ann Intern Med"},{"key":"859_CR27","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1001\/jama.2013.281361","volume":"311","author":"SN Yanovski","year":"2014","unstructured":"Yanovski SN, Yanovski JA. Long-term drug treatment of obesity: a systematic and clinical review. JAMA. 2014;311:74\u201386.","journal-title":"JAMA"},{"key":"859_CR28","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1136\/bmj.39385.413113.25","volume":"335","author":"D Rucker","year":"2007","unstructured":"Rucker D, Padwal R, Li SK, et al. Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ. 2007;335:1194\u20139.","journal-title":"BMJ"},{"key":"859_CR29","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1001\/jama.2016.7602","volume":"315","author":"R Khera","year":"2016","unstructured":"Khera R, Murad MH, Chandar A, et al. Association of pharmacological treatments for obesity with weight loss and adverse events. A systematic review and meta-analysis. JAMA. 2016;315:2424\u201334.","journal-title":"JAMA"},{"key":"859_CR30","unstructured":"Food and Drug Administration. Orlistat nonprescription briefing document: NDA 21\u2013887. Endocrine and metabolic drugs advisory committee meeting, January 23, 2006. Available at: http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/06\/briefing\/2006-4201B1_02_03-FDA-Clinical-Review.pdf . Accessed Jan 24, 2017."},{"key":"859_CR31","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1038\/sj.ijo.0803631","volume":"31","author":"R Padwal","year":"2007","unstructured":"Padwal R, Kezouh A, Levine M, Etminan M. Long-term persistence with orlistat and sibutramine in a population-based cohort. Int J Obes. 2007;31:1567\u201370.","journal-title":"Int J Obes"},{"key":"859_CR32","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/1098-2396(20010101)39:1<32::AID-SYN5>3.0.CO;2-3","volume":"39","author":"RB Rothman","year":"2001","unstructured":"Rothman RB, Baumann MH, Dersch CM, et al. Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse. 2001;39:32\u201341.","journal-title":"Synapse"},{"key":"859_CR33","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1002\/syn.20126","volume":"56","author":"M Alexander","year":"2005","unstructured":"Alexander M, Rothman RB, Baumann MH, et al. Noradrenergic and dopaminergic effects of (+)-amphetamine-like stimulants in the baboon Papio Anubis. Synapse. 2005;56:94\u20139.","journal-title":"Synapse"},{"key":"859_CR34","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1111\/j.1463-1326.2010.01242.x","volume":"12","author":"JG Kang","year":"2010","unstructured":"Kang JG, Park C-Y, Kang JH, et al. Randomized controlled trial to investigate the effects of a newly developed formulation of phentermine diffuse-controlled release for obesity. Diabetes Obes Metab. 2010;12:876\u201380.","journal-title":"Diabetes Obes Metab"},{"key":"859_CR35","doi-asserted-by":"crossref","first-page":"614","DOI":"10.3349\/ymj.2006.47.5.614","volume":"47","author":"KK Kim","year":"2006","unstructured":"Kim KK, Cho H-J, Kang H-C, et al. Effects of weight reduction and safety of short-term phentermine administration in Korean obese people. Yonsei Med J. 2006;47:614\u201325.","journal-title":"Yonsei Med J"},{"key":"859_CR36","doi-asserted-by":"crossref","first-page":"820","DOI":"10.2165\/00003495-199243060-00003","volume":"43","author":"T Silverstone","year":"1992","unstructured":"Silverstone T. Appetite suppressants: a review. Drugs. 1992;43:820\u201336.","journal-title":"Drugs"},{"key":"859_CR37","unstructured":"Prescribing information for Suprenza\u2122 (phentermine hydrochloride) orally disintegrating tablet. Akrimax Pharmaceuticals, Jan 2015."},{"key":"859_CR38","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1056\/NEJM199809103391102","volume":"339","author":"H Jick","year":"1998","unstructured":"Jick H, Vasilakis C, Weinrauch LA, et al. A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation. N Engl J Med. 1998;339:719\u201324.","journal-title":"N Engl J Med"},{"key":"859_CR39","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1161\/01.CIR.102.23.2836","volume":"102","author":"RB Rothman","year":"2000","unstructured":"Rothman RB, Baumann MH, Savage JE, et al. Evidence for possible involvement of 5-HT2B receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation. 2000;102:2836\u201341.","journal-title":"Circulation"},{"key":"859_CR40","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1016\/S0149-2918(97)80006-9","volume":"19","author":"WE Rosenfeld","year":"1997","unstructured":"Rosenfeld WE. Topiramate: a review of preclinical, pharmacokinetic, and clinical data. Clin Ther. 1997;19:1294\u2013308.","journal-title":"Clin Ther"},{"key":"859_CR41","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/oby.2003.78","volume":"11","author":"E Ben-Menachem","year":"2003","unstructured":"Ben-Menachem E, Sander JW, Johanson EH, et al. Predictors of weight loss in adults with topiramate treated epilepsy. Obes Res. 2003;11:556\u201362.","journal-title":"Obes Res"},{"key":"859_CR42","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.eplepsyres.2011.05.014","volume":"95","author":"A Verrotti","year":"2011","unstructured":"Verrotti A, Scaparrotta A, Agostinelli S, et al. Topiramate-induced weight loss: a review. Epilepsy Res. 2011;95:189\u201399.","journal-title":"Epilepsy Res"},{"key":"859_CR43","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/oby.2003.102","volume":"6","author":"GA Bray","year":"2003","unstructured":"Bray GA, Hollander P, Klein S, et al. A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity. Obes Res. 2003;6:722\u201333.","journal-title":"Obes Res"},{"key":"859_CR44","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1038\/sj.ijo.0802783","volume":"28","author":"J Wilding","year":"2004","unstructured":"Wilding J, Van Gaal L, Rissanen A, et al. A randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects. Int J Obes. 2004;28:1399\u2013410.","journal-title":"Int J Obes"},{"key":"859_CR45","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1038\/oby.2004.206","volume":"12","author":"A Astrup","year":"2004","unstructured":"Astrup A, Caterson I, Zelissen P, et al. Topiramate: long-term maintenance of weight loss induced by a low-calorie diet in obese subjects. Obes Res. 2004;12:1658\u201369.","journal-title":"Obes Res"},{"key":"859_CR46","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.amjcard.2005.03.053","volume":"96","author":"S Tonstad","year":"2005","unstructured":"Tonstad S, Tykarski A, Weissgarten J, et al. Efficacy and safety of topiramate in the treatment of obese subjects with essential hypertension. Am J Cardiol. 2005;96:243\u201351.","journal-title":"Am J Cardiol"},{"key":"859_CR47","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/j.1463-1326.2006.00618.x","volume":"9","author":"K Stenl\u00f6f","year":"2007","unstructured":"Stenl\u00f6f K, R\u00f6ssner S, Vercruysse F, et al. Topiramate in the treatment of obese subjects with drug-naive type 2 diabetes. Diabetes Obes Metab. 2007;9:360\u20138.","journal-title":"Diabetes Obes Metab"},{"key":"859_CR48","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1038\/sj.ijo.0803548","volume":"31","author":"B Eliasson","year":"2007","unstructured":"Eliasson B, Gudbj\u00f6rnsdottir S, Cederholm J, et al. Weight loss and metabolic effects of topiramate in overweight and obese type 2 diabetic patients: randomized double-blind placebo-controlled trial. Int J Obes. 2007;31:1140\u20137.","journal-title":"Int J Obes"},{"key":"859_CR49","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1038\/sj.ijo.0803382","volume":"31","author":"H Toplak","year":"2007","unstructured":"Toplak H, Hamann A, Moore R, et al. Efficacy and safety of topiramate in combination with metformin in the treatment of obese subjects with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Int J Obes. 2007;31:138\u201346.","journal-title":"Int J Obes"},{"key":"859_CR50","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.2337\/dc06-2001","volume":"30","author":"J Rosenstock","year":"2007","unstructured":"Rosenstock J, Hollander P, Gadde KM, et al. A randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of topiramate controlled release in the treatment of obese type 2 diabetic patients. Diabetes Care. 2007;30:1480\u20136.","journal-title":"Diabetes Care"},{"key":"859_CR51","doi-asserted-by":"crossref","first-page":"e338","DOI":"10.1111\/j.1467-789X.2010.00846.x","volume":"12","author":"CK Kramer","year":"2011","unstructured":"Kramer CK, Leitao CB, Pinto LC, et al. Efficacy and safety of topiramate on weight loss: a meta-analysis of randomized controlled trials. Obes Rev. 2011;12:e338\u201347.","journal-title":"Obes Rev"},{"key":"859_CR52","first-page":"A17","volume":"14","author":"KM Gadde","year":"2006","unstructured":"Gadde KM, Yonish GM, Foust MS, et al. A 24-week randomized controlled trial of VI-0521, a combination weight loss therapy, in obese adults. Obes Res. 2006;14:A17. abstract 406-P","journal-title":"Obes Res"},{"key":"859_CR53","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1002\/oby.20584","volume":"21","author":"LJ Aronne","year":"2013","unstructured":"Aronne LJ, Wadden TA, Peterson C, et al. Evaluation of phentermine and topiramate versus phentermine\/topiramate extended-release in obese adults. Obesity. 2013;21:2163\u201371.","journal-title":"Obesity"},{"key":"859_CR54","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/oby.2011.330","volume":"20","author":"DB Allison","year":"2012","unstructured":"Allison DB, Gadde KM, Garvey WT, et al. Controlled-release phentermine\/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity. 2012;20:330\u201342.","journal-title":"Obesity"},{"key":"859_CR55","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S0140-6736(11)60205-5","volume":"377","author":"KM Gadde","year":"2011","unstructured":"\u2022 Gadde KM, Allison DB, Ryan DH, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377:1341\u201352. Largest and most definitive phase 3 RCT of phentermine\/topiramate","journal-title":"Lancet"},{"key":"859_CR56","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3945\/ajcn.111.024927","volume":"95","author":"WT Garvey","year":"2012","unstructured":"Garvey WT, Ran DH, Look M, et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine\/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr. 2012;95:297\u2013308.","journal-title":"Am J Clin Nutr"},{"key":"859_CR57","unstructured":"Food and Drug Administration. Advisory committee meeting for phentermine\/topiramate (Qnexa), July 15, 2010. Division of Metabolism and Endocrinology Products (DMEP), Office of Drug Evaluation II, Center for Drug Evaluation and Research, Silver Spring, MD. Available at: http:\/\/www.fda.gov\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/EndocrinologicandMetabolicDrugsAdvisoryCommittee\/ucm218819.htm . Accessed Jan 23, 2017."},{"key":"859_CR58","unstructured":"Food and Drug Administration. FDA news release: FDA approves weight-management drug Qsymia. Available at: http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm312468.htm . Accessed Jan 23, 2017."},{"key":"859_CR59","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1212\/WNL.0b013e3182574f39","volume":"78","author":"S Hern\u00e1ndez-D\u00edaz","year":"2012","unstructured":"Hern\u00e1ndez-D\u00edaz S, Smith CR, Shen A, et al. Comparative safety of antiepileptic drugs during pregnancy. Neurology. 2012;78:1692\u20139.","journal-title":"Neurology"},{"key":"859_CR60","doi-asserted-by":"crossref","first-page":"405e1","DOI":"10.1016\/j.ajog.2012.07.008","volume":"207","author":"AV Margulis","year":"2012","unstructured":"Margulis AV, Mitchell AA, Gilboa SM, et al. Use of topiramate in pregnancy and risk of oral clefts. Am J Obstet Gynecol. 2012;207:405e1\u20137.","journal-title":"Am J Obstet Gynecol"},{"key":"859_CR61","unstructured":"Vivus, Inc. NDA 22580. Qsymia (phentermine and topiramate extended-release) Capsules: risk evaluation and mitigation strategy (REMS). Initial REMS approval, 07\/2012; most recent modification, 09\/2014. Available at: http:\/\/www.fda.gov\/downloads\/Drugs\/DrugSafety\/postmarketdrugsafetyinformationforpatientsandproviders\/UCM312598.pdf . Accessed Jan 23, 2017."},{"key":"859_CR62","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/oby.2001.71","volume":"9","author":"KM Gadde","year":"2001","unstructured":"\u2022 Gadde KM, Parker CB, Maner LG, et al. Bupropion for weight loss: an investigation of efficacy and tolerability in overweight and obese women. Obes Res. 2001;9:544\u201351. First RCT of bupropion for weight loss in obese adults","journal-title":"Obes Res"},{"key":"859_CR63","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1038\/oby.2002.142","volume":"10","author":"AK Jain","year":"2002","unstructured":"Jain AK, Kaplan RA, Gadde KM, et al. Bupropion SR vs. placebo for weight loss in obese patients with depressive symptoms. Obes Res. 2002;10:1049\u201356.","journal-title":"Obes Res"},{"key":"859_CR64","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/clpt.1985.197","volume":"38","author":"RL Atkinson","year":"1985","unstructured":"Atkinson RL, Berke LK, Drake CR, et al. Effects of long-term therapy with naltrexone on body weight in obesity. Clin Pharmacol Ther. 1985;38:419\u201322.","journal-title":"Clin Pharmacol Ther"},{"key":"859_CR65","first-page":"347","volume":"9","author":"R Malcolm","year":"1985","unstructured":"Malcolm R, O\u2019Neil PM, Sexauer JD, et al. A controlled trial of naltrexone in obese humans. Int J Obes. 1985;9:347\u201353.","journal-title":"Int J Obes"},{"key":"859_CR66","unstructured":"United States Patent and Trademark Office. United States patent 7,462,626, December 9, 2008. Compositions for affecting weight loss. Available at: http:\/\/patft.uspto.gov\/netacgi\/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=14&f=G&l=50&co1=AND&d=PTXT&s1=7462626&OS=7462626&RS=7462626 . Accessed Jan 23, 2017."},{"key":"859_CR67","unstructured":"Orexigen Therapeutics. Contrave (Naltrexone SR\/Bupropion SR combination), NDA 200063. Advisory committee briefing document. Endocrinologic and Metabolic Drugs Advisory Committee Meeting, December 7, 2010. Available at: http:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/EndocrinologicandMetabolicDrugsAdvisoryCommittee\/UCM235672.pdf . Accessed Jan 23, 2017."},{"key":"859_CR68","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/oby.2008.461","volume":"17","author":"FL Greenway","year":"2009","unstructured":"Greenway FL, Whitehouse MJ, Guttadauria M, et al. Rational design of a combination medication for the treatment of obesity. Obesity. 2009;17:30\u20139.","journal-title":"Obesity"},{"key":"859_CR69","doi-asserted-by":"crossref","first-page":"4898","DOI":"10.1210\/jc.2009-1350","volume":"94","author":"FL Greenway","year":"2009","unstructured":"Greenway FL, Dunayevich E, Tollefson G, et al. Comparison of combined bupropion and naltrexone therapy for obesity with monotherapy and placebo. J Endocrinol Metab. 2009;94:4898\u2013906.","journal-title":"J Endocrinol Metab"},{"key":"859_CR70","unstructured":"Food and Drug Administration. FDA briefing document, NDA 200063. Advisory committee meeting for naltrexone\/bupropion (Contrave), Endocrinologic & Metabolic Drugs Advisory Committee, 7 Dec 2010. Available at: http:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/EndocrinologicandMetabolicDrugsAdvisoryCommittee\/UCM235671.pdf . Accessed Jan 23, 2017."},{"key":"859_CR71","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1001\/jama.2016.1558","volume":"315","author":"SE Nissen","year":"2016","unstructured":"\u2022 Nissen SE, Wolski KE, Prcela L, et al. Effect of naltrexone-bupropion on major adverse cardiovascular events in overweight and obese patients with cardiovascular risk factors: a randomized clinical trial. JAMA. 2016;315:990\u20131004. Largest and longest study of naltrexone\/bupropion designed to investigate the risk of major adverse cardiovascular events","journal-title":"JAMA"},{"key":"859_CR72","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1124\/jpet.107.133348","volume":"325","author":"WJ Thomsen","year":"2008","unstructured":"Thomsen WJ, Grottick AJ, Menzaghi F, et al. Lorcaserin, a novel selective human 5-hydroxytryptamine2C agonist: in vitro and in vivo pharmacological characterization. J Pharmacol Exp Ther. 2008;325:577\u201387.","journal-title":"J Pharmacol Exp Ther"},{"key":"859_CR73","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1056\/NEJMoa0909809","volume":"363","author":"DR Smith","year":"2010","unstructured":"\u2022 Smith DR, Weissman NJ, Anderson CM, et al. Behavior modification and lorcaserin for overweight and obesity management (BLOOM) study group: multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med. 2010;363:245\u201356. Largest and longest published RCT of lorcaserin","journal-title":"N Engl J Med"},{"key":"859_CR74","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1210\/jc.2011-1256","volume":"96","author":"MC Fidler","year":"2011","unstructured":"Fidler MC, Sanchez M, Raether B, et al. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial. J Clin Endocrinol Metab. 2011;96:3067\u201377.","journal-title":"J Clin Endocrinol Metab"},{"key":"859_CR75","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1038\/oby.2012.66","volume":"20","author":"PM O\u2019Neil","year":"2012","unstructured":"O\u2019Neil PM, Smith SR, Weissman NJ, et al. Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study. Obesity. 2012;20:1426\u201336.","journal-title":"Obesity"},{"key":"859_CR76","unstructured":"Food and Drug Administration. FDA briefing document, NDA 22529. Advisory committee meeting for lorcaserin. Endocrinologic & Metabolic Drugs Advisory Committee, 16 Sep 2010. Available at: http:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/EndocrinologicandMetabolicDrugsAdvisoryCommittee\/UCM225631.pdf . Accessed Jan 23, 2017."},{"key":"859_CR77","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJMp1211277","volume":"367","author":"E Colman","year":"2012","unstructured":"Colman E, Golden J, Roberts M, et al. The FDA\u2019s assessment of two drugs for chronic weight management. N Engl J Med. 2012;367:1577\u20138.","journal-title":"N Engl J Med"},{"key":"859_CR78","unstructured":"Eisai, Inc. A study to evaluate the effect of long-term treatment with BELVIQ (Lorcaserin HCl) on the incidence of major adverse cardiovascular events and conversion to type 2 diabetes mellitus in obese and overweight subjects with cardiovascular disease or multiple cardiovascular risk factors (CAMELLIA-TIMI). ClinicalTrials.gov Identifier NCT 02019264. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02019264?term=lorcaserin+cardiovascular&rank=1 . Accessed Jan 23, 2017."},{"key":"859_CR79","unstructured":"Prescribing information for Belviq\u00ae (lorcaserin HCl) for oral use, CIV. Arena Pharmaceuticals, Zofingen, Switzerland, and Eisai, Inc., Woodcliff Lake, NJ, Dec 2015."},{"key":"859_CR80","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1038\/sj.ijo.0801627","volume":"25","author":"A Flint","year":"2001","unstructured":"Flint A, Raben A, Ak E, et al. The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, and energy and substrate metabolism in obesity. Int J Obes. 2001;25:781\u201392.","journal-title":"Int J Obes"},{"key":"859_CR81","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1172\/JCI72434","volume":"124","author":"S Sisley","year":"2014","unstructured":"Sisley S, Gutierrez-Aguilar R, Scott M, et al. Neuronal GLP1R mediates liraglutide\u2019s anorectic but not glucose-lowering effect. J Clin Invest. 2014;124:2456\u201363.","journal-title":"J Clin Invest"},{"key":"859_CR82","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/S0140-6736(09)61375-1","volume":"374","author":"A Astrup","year":"2009","unstructured":"Astrup A, R\u00f6ssner S, Van Gaal L, et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet. 2009;374:1606\u201316.","journal-title":"Lancet"},{"key":"859_CR83","unstructured":"Food and Drug Administration. FDA briefing document, NDA 206321, liraglutide injection, 3 mg. Endocrinologic and Metabolic Drugs Advisory Committee meeting, 11 September 2014. Available at: http:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/EndocrinologicandMetabolicDrugsAdvisoryCommittee\/UCM413317.pdf . Accessed Jan 23, 2017."},{"key":"859_CR84","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1411892","volume":"373","author":"X Pi-Sunyer","year":"2015","unstructured":"\u2022 Pi-Sunyer X, Astrup A, Fujioka K, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015;373:11\u201322. Largest phase 3 RCT of liraglutide","journal-title":"N Engl J Med"},{"key":"859_CR85","doi-asserted-by":"publisher","unstructured":"le Roux CW, Astrup A, Fujioka K, et al. Three years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. Lancet. 2017. doi: 10.1016\/S0140-6736(17)30069-7 .","DOI":"10.1016\/S0140-6736(17)30069-7"},{"key":"859_CR86","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1001\/jama.2015.9676","volume":"314","author":"MJ Davies","year":"2015","unstructured":"Davies MJ, Bergenstal R, Bode B, et al. Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial. JAMA. 2015;314:687\u201399.","journal-title":"JAMA"},{"key":"859_CR87","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1038\/ijo.2016.52","volume":"40","author":"A Blackman","year":"2016","unstructured":"Blackman A, Foster GD, Zammit G, et al. Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE sleep apnea randomized clinical trial. Int J Obes. 2016;40:1310\u20139.","journal-title":"Int J Obes"},{"key":"859_CR88","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311\u201322.","journal-title":"N Engl J Med"}],"container-title":["Current Diabetes Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11892-017-0859-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11892-017-0859-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11892-017-0859-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T20:43:23Z","timestamp":1750193003000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11892-017-0859-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,4]]},"references-count":88,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["859"],"URL":"https:\/\/doi.org\/10.1007\/s11892-017-0859-2","relation":{},"ISSN":["1534-4827","1539-0829"],"issn-type":[{"value":"1534-4827","type":"print"},{"value":"1539-0829","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,4]]},"article-number":"34"}}